세계의 동물용 항생제 시장 : 클래스별, 동물 유형별, 최종 사용자별, 치료영역별, 예측(2025-2030년)

The Veterinary Antibiotics Market was valued at USD 2.58 billion in 2023 and is projected to grow to USD 2.81 billion in 2024, with a CAGR of 9.01%, reaching USD 4.73 billion by 2030.

Veterinary antibiotics continue to reshape the landscape of animal health management and treatment, playing a critical role in safeguarding both animal and human populations. The executive summary presents an in-depth analysis of the current state and evolving trends in the veterinary antibiotics market, addressing challenges and opportunities created by emerging antibiotic resistance, regulatory pressures, and evolving market dynamics. This analysis underscores the importance of rigorous research and targeted research methodologies to capture the intricacies of an industry undergoing rapid transformation. In today's highly competitive global environment, stakeholders-from pharmaceutical developers to veterinary practitioners-are recognizing the necessity of aligning their strategies with detailed, data-driven insights. The purpose of this report is to present a comprehensive overview of the market dynamics while providing actionable insights that support strategic decision-making within a field that continues to expand in both complexity and scope.

Our discussion begins with a reflection on the historical perspective of veterinary antibiotics as a foundation, gradually progressing to an examination of groundbreaking changes and technological innovations that are redefining market expectations. The importance of adhering to high standards of efficacy, safety, and environmental considerations is interwoven throughout the narrative, ensuring that industry leaders are well prepared to address contemporary issues such as regulatory realignment, global supply chain adaptation, and the emerging need for antibiotic stewardship. By laying the groundwork with a robust introduction, we set the stage for a deep dive into a market that is both highly dynamic and essential to modern animal health care.

Transformative Shifts in the Veterinary Antibiotics Landscape

In recent years, the veterinary antibiotics market has experienced transformative shifts that are fundamentally altering the way professionals address both longstanding and emergent challenges. Technological innovations, regulatory changes, and evolving market dynamics have converged to drive the development of more targeted and efficient antibiotic therapies.

One of the most significant shifts in the landscape is the transition toward precision veterinary medicine. With advances in diagnostic technologies and genetic profiling, there is a growing ability to tailor antibiotic treatments to specific bacterial pathogens and infections. This precision approach not only improves treatment outcomes but also plays a pivotal role in reducing the emergence of resistance from widespread or empirical antibiotic use.

Changing regulatory frameworks have also played an essential role in catalyzing market transformations. Increased scrutiny regarding the use of antibiotics in animal agriculture, combined with stringent safety protocols, has led to the development of new guidelines that emphasize responsible usage. These evolving regulations are prompting industry stakeholders to adapt quickly, investing in research and development to create novel formulations that comply with higher standards while maintaining therapeutic efficacy.

Additionally, market dynamics are being influenced by heightened consumer awareness and an increased emphasis on the health of companion animals. As pet owners become more conscientious about the treatments administered to their beloved animals, pharmaceutical companies have initiated programs to educate and train veterinary professionals, ensuring that antibiotic prescription practices are aligned with contemporary research findings and responsible medication protocols.

This stage of transformation is complemented by robust efforts in sustainability, particularly the development of innovations aimed at reducing environmental residues and limiting ecological impacts. The combined effects of enhanced diagnostic techniques, more comprehensive regulations, and growing consumer awareness are driving a market that increasingly prioritizes precision, safety, and sustainable practices, ensuring that the use of veterinary antibiotics is both scientifically grounded and ethically managed.

Key Segmentation Insights into Class, Animal Type, End-User, and Therapeutic Areas

A detailed segmentation of the veterinary antibiotics market provides a multi-dimensional understanding of the industry, unveiling intricate patterns and opportunities for growth. The market has been categorized from multiple perspectives, such as the class of antibiotics, the type of animal receiving treatment, the end-user setting, and the therapeutic areas that outline the range of infections treated. By examining the market based on these diverse segmentation criteria, one can identify trends that allow for more targeted and effective strategic decisions.

When considering the classification of antibiotics, it is evident that a variety of drug classes such as Aminoglycosides, Amphenicols, Cephalosporins, Fluoroquinolones, Macrolides, Other Quinolones, Penicillins, Polymixins, Sulfonamides, Tetracyclines, and Trimethoprim have been studied comprehensively. These classes are further subdivided for granular analysis, with Aminoglycosides including drugs such as Amikacin, Apramycin, Gentamicin, Kanamycin, and Neomycin, each offering unique characteristics for treating resistant infections. Similarly, Amphenicols are further delineated to include compounds like Azidamfenicol, Chloramphenicol, Florfenicol, Metiamycin, and Thiamphenicol. In the same manner, the Cephalosporins group is broken down to explore the specific market niches of Cefalexin, Cefalonium, Cefazolin, Cefovecin, Ceftiofur, and Ceftriaxone, enabling a more focused approach when addressing bacterial resistance. With Fluoroquinolones, research encompasses Ciprofloxacin, Danofloxacin, Difloxacin, Enrofloxacin, Norfloxacin, and Orbifloxacin, while Macrolides such as Azithromycin, Clarithromycin, Erythromycin, Gamithromycin, Spiramycin, Tilmicosin, Tulathromycin, and Tylosin are analyzed in parallel. Similarly, the portfolio of Other Quinolones-which includes Cinoxacin, Nalidixic Acid, Oxolinic Acid, Pipemidic Acid, and Rosoxacin-is scrutinized to better understand its market potential. The division of Penicillins into sub-categories featuring Amoxicillin, Ampicillin, Cloxacillin, Oxacillin, Penicillin G, and Penicillin V enables focused insights that drive product differentiation. Moreover, the Polymixins segment is further demarcated into Colistin/Polymyxin E and Polymyxin B, while the Sulfonamides class is detailed by studying Sulfadiazine, Sulfamerazine, Sulfamethizole, Sulfamethoxazole, and Sulfasalazine. The Tetracyclines are analyzed across variations such as Chlortetracycline, Doxycycline, Oxytetracycline, and Tetracycline, and the Trimethoprim class is segmented to explore combinations like Trimethoprim Plus Sulfamethazine, Trimethoprim-Sulfadiazine, Trimethoprim-Sulfadimidine, Trimethoprim-Sulfadoxine, and Trimethoprim-Sulfamethoxazole.

Apart from the intricate drug classifications, analyzing the market by animal type reveals unique trends based on the character of the treated animal. The market traditionally divides into two essential segments-Companion Animals and Livestock. Within the sphere of companion animals, treatments are primarily directed toward common household pets, particularly cats and dogs, where therapeutic approaches need to balance efficacy and safety in delicate physiological environments. Conversely, the livestock segment includes a broader array of animals such as cattle, poultry, sheep and goats, and swine. These groups require tailored treatment strategies reflective of changing husbandry practices, species-specific physiology, and the critical importance of ensuring the food chain's safety.

Furthermore, the segmentation based on end-user settings provides insights into the channel dynamics that shape the market ecosystem. The utilization in specialized animal production facilities is driven by the need for scale and efficiency. This is complemented by the consumer-driven usage patterns observed among household pet owners, where a focus on individualized care is paramount. The role of veterinary clinics remains invaluable, as these institutions act as the interface between advanced research and practical, on-ground application, creating a fertile ground for innovative antibiotic therapies.

Finally, the exploration of therapeutic areas within the market underscores the wide range of applications associated with veterinary antibiotics. Assessment covers a series of therapeutic challenges including dermatological infections, gastrointestinal infections, infections of the reproductive system, respiratory infections, soft tissue and wound infections, systemic infections, and urinary tract infections. By correlating these therapeutic areas with the specific needs of different animal segments, stakeholders are enabled to tailor interventions based on both economic and clinical metrics, ensuring that each application area is optimally served through targeted research, timely innovation, and customized treatment protocols.

In summary, segmentation reveals the complex and layered nature of the veterinary antibiotics market. It is this detailed and structured approach that allows for an in-depth understanding of both macro and micro-level trends, laying the foundation for precise market targeting and the identification of latent opportunities within every sub-segment.

Based on Class, market is studied across Aminoglycosides, Amphenicols, Cephalosporins, Fluoroquinolones, Macrolides, Other Quinolones, Penicillins, Polymixins, Sulfonamides, Tetracyclines, and Trimethoprim. The Aminoglycosides is further studied across Amikacin, Apramycin, Gentamicin, Kanamycin, and Neomycin. The Amphenicols is further studied across Azidamfenicol, Chloramphenicol, Florfenicol, Metiamycin, and Thiamphenicol. The Cephalosporins is further studied across Cefalexin, Cefalonium, Cefazolin, Cefovecin, Ceftiofur, and Ceftriaxone. The Fluoroquinolones is further studied across Ciprofloxacin, Danofloxacin, Difloxacin, Enrofloxacin, Norfloxacin, and Orbifloxacin. The Macrolides is further studied across Azithromycin, Clarithromycin, Erythromycin, Gamithromycin, Spiramycin, Tilmicosin, Tulathromycin, and Tylosin. The Other Quinolones is further studied across Cinoxacin, Nalidixic Acid, Oxolinic Acid, Pipemidic Acid, and Rosoxacin. The Penicillins is further studied across Amoxicillin, Ampicillin, Cloxacillin, Oxacillin, Penicillin G, and Penicillin V. The Polymixins is further studied across Colistin/Polymyxin E and Polymyxin B. The Sulfonamides is further studied across Sulfadiazine, Sulfamerazine, Sulfamethizole, Sulfamethoxazole, and Sulfasalazine. The Tetracyclines is further studied across Chlortetracycline, Doxycycline, Oxytetracycline, and Tetracycline. The Trimethoprim is further studied across Trimethoprim Plus Sulfamethazine, Trimethoprim-Sulfadiazine, Trimethoprim-Sulfadimidine, Trimethoprim-Sulfadoxine, and Trimethoprim-Sulfamethoxazole (TMP-SMX).

Based on Animal Type, market is studied across Companion Animals and Livestock. The Companion Animals is further studied across Cats and Dogs. The Livestock is further studied across Cattle, Poultry, Sheep & Goats, and Swine.

Based on End-User, market is studied across Animal Production Facilities, Household Pet Owners, and Veterinary Clinics.

Based on Therapeutic Areas, market is studied across Dermatological Infections, Gastrointestinal Infections, Reproductive System Infections, Respiratory Infections, Soft Tissue & Wound Infections, Systemic Infections, and Urinary Tract Infections.

Analyzing Key Regional Insights Across Global Markets

A meticulous examination of the geographic landscape illustrates significant regional disparities and growth drivers that influence the global veterinary antibiotics market. The distinct markets in the Americas, Europe, Middle East & Africa, and Asia-Pacific each present unique characteristics that not only reflect local economic and regulatory conditions but also denote significant potential for strategic expansion and investment.

In the Americas, market dynamics have been marked by a swift adaptation to evolving regulatory frameworks and heightened consumer awareness regarding animal welfare and public health. These factors have spurred market growth, supported by high adoption rates of precision treatments and modern therapeutic approaches in both companion animal and livestock sectors. Regional economic stability and an increasing focus on innovation have bolstered research and development initiatives, enabling breakthroughs in treatment efficacy and safety.

Europe, along with the Middle East & Africa, exhibits a complex interplay of regulatory restrictions and collaborative research. European markets in particular benefit from a highly regulated environment, necessitating strict compliance and comprehensive stewardship measures that influence product development pipelines. The focus on sustainability and environmental protection further encourages the development of antibiotics with reduced ecological footprints. In the Middle East & Africa, market growth is driven by a rising demand for improved animal health protocols as emerging economies invest in modernizing their agricultural practices and veterinary care systems. These regions are witnessing increasing governmental support for enhanced veterinary services, indirectly fostering expansions in the availability and diversity of antibiotic treatments.

The Asia-Pacific market is distinguished by dynamic economic growth and rapid urbanization that are reshaping livestock practices and pet ownership trends. Increased disposable incomes, accelerated technological adoption, and expanding consumer bases in emerging countries contribute to the heightened demand for state-of-the-art veterinary care. The region's market is characterized by high-volume production of veterinary antibiotics tailored to meet diverse requirements across both extensive livestock operations and the evolving pet care segment. Additionally, the Asia-Pacific markets frequently benefit from proactive public and private partnerships which drive investments into research, manufacturing efficiency, and the integration of global best practices in veterinary medicine.

Altogether, the divergence and distinctiveness of regional markets underscore the importance of localized strategies that consider cultural, economic, and regulatory factors. A deep understanding of these geographical nuances enables stakeholders to harness growth opportunities tailored to specific markets while maintaining a cohesive global strategy that leverages innovation and sustainability.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Profile of Leading Companies Driving Growth and Innovation

The competitive landscape of the veterinary antibiotics market is spearheaded by a dynamic cohort of companies, each contributing to the sector's innovation and market expansion. In this environment, organizations such as Ashish Life Science Private Limited, Bimeda Inc., and Biogenesis Bago S.A. have differentiated themselves through rigorous research and a steadfast commitment to high-quality product portfolios. These companies have become known for integrating cutting-edge technologies into their production processes, resulting in therapies that are both effective and safe.

Other industry leaders, including C.H. Boehringer Sohn AG & Co. KG and Ceva Sante Animale, have built strong reputations by leveraging deep expertise in both human and veterinary pharmaceuticals. They maintain strategic collaborations with research institutions, enabling them to keep pace with the rapidly evolving scientific environment and ensure that their product offerings are based on the latest clinical evidence. Dechra Pharmaceuticals PLC, Eco Animal Health Group PLC, and Elanco Animal Health Incorporated also play critical roles, driving market growth through focused investment in research and an unyielding commitment to meeting modern regulatory standards.

Intas Pharmaceuticals Ltd., along with established entities such as Krka, d. d., Novo mesto, continues to expand their presence by capitalizing on innovation and diversification of product pipelines. Kyoritsuseiyaku Corporation and LABORATORIO AVI-MEX represent robust contributors in this competitive landscape, underscoring the ever-more global reach of the industry. LABORATORIOS CALIER, S.A., Merck KGaA, Neogen Corporation, and Ourofino Group have all demonstrated a capacity to adapt to shifting market demands through agile business strategies and the consistent delivery of high-performance therapies. Moreover, companies like Sequent Scientific Ltd., Vetoquinol SA, Virbac SA, and Zoetis Inc. have reinforced their market positions through strategic acquisitions, expansive research initiatives, and a deep-rooted dedication to advancing animal health. Their comprehensive and specialized portfolios enable them to meet a diverse range of veterinary needs while staying competitive amid evolving industry trends.

The robust profile of these key companies reflects an unwavering commitment to innovation, quality, and customer-centric solutions. By continuously investing in research and embracing strategic mergers and alliances, these leading players are not only bolstering their market shares but also contributing to significant advancements that are shaping the future of veterinary medicine. Their efforts are driving improvements in both therapeutic efficacy and sustainable practices, ensuring that animal health remains at the forefront of the global veterinary antibiotics market.

The report delves into recent significant developments in the Veterinary Antibiotics Market, highlighting leading vendors and their innovative profiles. These include Ashish Life Science Private Limited, Bimeda Inc., Biogenesis Bago S.A., C.H. Boehringer Sohn AG & Co. KG, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Eco Animal Health Group PLC, Elanco Animal Health Incorporated, Intas Pharmaceuticals Ltd., Krka, d. d., Novo mesto, Kyoritsuseiyaku Corporation, LABORATORIO AVI-MEX, LABORATORIOS CALIER, S.A., Merck KGaA, Neogen Corporation, Ourofino Group, Sequent Scientific Ltd., Vetoquinol SA, Virbac SA, and Zoetis Inc.. Actionable Recommendations to Enhance Market Positioning and Growth

For industry leaders seeking to capitalize on emerging trends and reinforce their market positioning, several actionable recommendations can be drawn from the current analysis. Foremost, a sustained commitment to research and development is essential. Leaders should invest in innovative diagnostic technologies and precision medicine approaches, thereby enabling the creation of targeted antibiotic therapies that not only improve treatment outcomes but also address concerns related to antimicrobial resistance.

It is equally important for decision-makers to prioritize regulatory compliance and proactive engagement with evolving legislation. By maintaining close collaboration with regulatory bodies and ensuring that product development strategies are aligned with globally recognized standards, companies can safeguard their market presence and avert potential setbacks related to non-compliance.

In addition, market expansion strategies should be driven by a granular understanding of regional dynamics. Firms need to tailor their approaches based on detailed insights into the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. This localized strategy will enable companies to optimize resource allocation, adapt product formulations to meet specific regional requirements, and leverage partnerships with local stakeholders to enhance distribution networks.

Another key consideration is the embrace of digital transformation. Investing in advanced analytics and artificial intelligence can provide real-time insights into market trends, customer behavior, and competitive activity. A data-driven approach not only enhances decision-making processes but also ensures agile responses to rapid market changes. Furthermore, companies would benefit by expanding collaborations with research institutions and industry experts to foster innovation and develop sustainable practices that lessen environmental impact.

Finally, organizations must adopt a customer-centric model that emphasizes tailored solutions in both companion animal and livestock segments. This approach requires continuous engagement with veterinary practitioners, training initiatives for end users, and comprehensive support systems that ensure the successful implementation of new therapies. By integrating these strategies, industry leaders can solidify their competitive edge, drive sustainable growth, and contribute positively to the broader narrative of veterinary healthcare innovation.

Concluding Reflections on the Veterinary Antibiotics Market

The comprehensive analysis underscores the intricate dynamics underpinning the current and future state of the veterinary antibiotics market. This exploration has traversed a spectrum of key dimensions, from transformative innovations and nuanced segmentation insights to region-specific trends and the strategic moves of industry titans. At every level, the narrative reveals a market that is not only vast in its complexity but also rich with opportunities for investment, growth, and sustainable development.

A critical takeaway from this review is the importance of balancing rapid technological advancements with steadfast commitments to safety, regulatory compliance, and environmental considerations. The sector's evolution is being driven by a robust demand for precision in animal health interventions, alongside an urgent need to mitigate issues related to antimicrobial resistance. As veterinary professionals and industry stakeholders capitalize on these trends, it becomes evident that success will depend on an adaptive approach that embraces both local nuances and global best practices.

The integrated insights presented herein serve not only as a reflection of the market condition but also as a roadmap for future strategic directions. The interplay between scientific innovation, regulatory evolution, and market expansion creates a fertile ground for further breakthroughs, ultimately driving enhanced health outcomes for animals across various segments. Reflecting on these factors, it is clear that the veterinary antibiotics market is poised to offer substantial rewards for those who navigate its challenges with foresight and strategic agility.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing livestock population with increasing demand for dairy and meat products
    • 5.1.1.2. Rising prevalence of zoonotic diseases and other infections in animals
    • 5.1.1.3. Increasing companionship and humanization of pets across the globe
  • 5.1.2. Restraints
    • 5.1.2.1. Growing concerns about antibiotic resistance in veterinary disease antigens
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in drug delivery systems that enhance the efficacy and safety of veterinary antibiotics
    • 5.1.3.2. Growing potential with the development of new antibiotics with novel mechanisms
  • 5.1.4. Challenges
    • 5.1.4.1. Issues related to the ban and restricted use of veterinary antibiotics in different regions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Class: Rising demand for amphenicols in various countries for treating respiratory diseases in cattle and fish
  • 5.2.2. Animal Type: Usage of veterinary-antibiotics livestocks to ensure safe food supply chains and economic stability for farmers
  • 5.2.3. End-User: Adoption of veterinary antibiotics in animal production facilities to prevent disease outbreaks and ensure optimal growth rates.
  • 5.2.4. Therapeutic Areas: Utilization of veterinary antibiotics in respiratory infection to prevent outbreaks and maintain herd health,
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Veterinary Antibiotics Market, by Class

• 6.1. Introduction
• 6.2. Aminoglycosides
  • 6.2.1. Amikacin
  • 6.2.2. Apramycin
  • 6.2.3. Gentamicin
  • 6.2.4. Kanamycin
  • 6.2.5. Neomycin
• 6.3. Amphenicols
  • 6.3.1. Azidamfenicol
  • 6.3.2. Chloramphenicol
  • 6.3.3. Florfenicol
  • 6.3.4. Metiamycin
  • 6.3.5. Thiamphenicol
• 6.4. Cephalosporins
  • 6.4.1. Cefalexin
  • 6.4.2. Cefalonium
  • 6.4.3. Cefazolin
  • 6.4.4. Cefovecin
  • 6.4.5. Ceftiofur
  • 6.4.6. Ceftriaxone
• 6.5. Fluoroquinolones
  • 6.5.1. Ciprofloxacin
  • 6.5.2. Danofloxacin
  • 6.5.3. Difloxacin
  • 6.5.4. Enrofloxacin
  • 6.5.5. Norfloxacin
  • 6.5.6. Orbifloxacin
• 6.6. Macrolides
  • 6.6.1. Azithromycin
  • 6.6.2. Clarithromycin
  • 6.6.3. Erythromycin
  • 6.6.4. Gamithromycin
  • 6.6.5. Spiramycin
  • 6.6.6. Tilmicosin
  • 6.6.7. Tulathromycin
  • 6.6.8. Tylosin
• 6.7. Other Quinolones
  • 6.7.1. Cinoxacin
  • 6.7.2. Nalidixic Acid
  • 6.7.3. Oxolinic Acid
  • 6.7.4. Pipemidic Acid
  • 6.7.5. Rosoxacin
• 6.8. Penicillins
  • 6.8.1. Amoxicillin
  • 6.8.2. Ampicillin
  • 6.8.3. Cloxacillin
  • 6.8.4. Oxacillin
  • 6.8.5. Penicillin G
  • 6.8.6. Penicillin V
• 6.9. Polymixins
  • 6.9.1. Colistin/Polymyxin E
  • 6.9.2. Polymyxin B
• 6.10. Sulfonamides
  • 6.10.1. Sulfadiazine
  • 6.10.2. Sulfamerazine
  • 6.10.3. Sulfamethizole
  • 6.10.4. Sulfamethoxazole
  • 6.10.5. Sulfasalazine
• 6.11. Tetracyclines
  • 6.11.1. Chlortetracycline
  • 6.11.2. Doxycycline
  • 6.11.3. Oxytetracycline
  • 6.11.4. Tetracycline
• 6.12. Trimethoprim
  • 6.12.1. Trimethoprim Plus Sulfamethazine
  • 6.12.2. Trimethoprim-Sulfadiazine
  • 6.12.3. Trimethoprim-Sulfadimidine
  • 6.12.4. Trimethoprim-Sulfadoxine
  • 6.12.5. Trimethoprim-Sulfamethoxazole (TMP-SMX)

7. Veterinary Antibiotics Market, by Animal Type

• 7.1. Introduction
• 7.2. Companion Animals
  • 7.2.1. Cats
  • 7.2.2. Dogs
• 7.3. Livestock
  • 7.3.1. Cattle
  • 7.3.2. Poultry
  • 7.3.3. Sheep & Goats
  • 7.3.4. Swine

8. Veterinary Antibiotics Market, by End-User

• 8.1. Introduction
• 8.2. Animal Production Facilities
• 8.3. Household Pet Owners
• 8.4. Veterinary Clinics

9. Veterinary Antibiotics Market, by Therapeutic Areas

• 9.1. Introduction
• 9.2. Dermatological Infections
• 9.3. Gastrointestinal Infections
• 9.4. Reproductive System Infections
• 9.5. Respiratory Infections
• 9.6. Soft Tissue & Wound Infections
• 9.7. Systemic Infections
• 9.8. Urinary Tract Infections

10. Americas Veterinary Antibiotics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Veterinary Antibiotics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Veterinary Antibiotics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Innovative Vetlen pouch enhances antibiotic delivery for veterinary care
  • 13.3.2. Innovative antibacterial agents target antibiotic-resistant infections
  • 13.3.3. FDA establishes veterinary innovation centers to advance animal health
  • 13.3.4. Purdue and Akston Biosciences partner for innovative canine cancer treatment development
  • 13.3.5. Dechra Pharmaceuticals to acquire invetx for enhanced veterinary biotherapeutics portfolio
  • 13.3.6. FDA approves pradalex for targeted Use in cattle and swine respiratory treatment
  • 13.3.7. Blacksmith Medicines and Zoetis collaborate to tackle antibiotic resistance in animal health
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. Intas Pharmaceuticals Ltd.
  • 13.4.2. Merck KGaA
  • 13.4.3. Elanco Animal Health Incorporated
  • 13.4.4. Zoetis Inc.

Companies Mentioned

• 1. Ashish Life Science Private Limited
• 2. Bimeda Inc.
• 3. Biogenesis Bago S.A.
• 4. C.H. Boehringer Sohn AG & Co. KG
• 5. Ceva Sante Animale
• 6. Dechra Pharmaceuticals PLC
• 7. Eco Animal Health Group PLC
• 8. Elanco Animal Health Incorporated
• 9. Intas Pharmaceuticals Ltd.
• 10. Krka, d. d., Novo mesto
• 11. Kyoritsuseiyaku Corporation
• 12. LABORATORIO AVI-MEX
• 13. LABORATORIOS CALIER, S.A.
• 14. Merck KGaA
• 15. Neogen Corporation
• 16. Ourofino Group
• 17. Sequent Scientific Ltd.
• 18. Vetoquinol SA
• 19. Virbac SA
• 20. Zoetis Inc.